Core Insights - Deep Longevity, Inc is set to expand into the U.S. market in Q1 2026, targeting the rapidly growing health market valued at over $6.8 trillion [1][2] - The company offers clinically validated aging clocks that provide multi-dimensional biological age assessments, surpassing chronological age [1] - Deep Longevity aims to establish a local sales team in the U.S. to drive partnerships with various health-related entities [2] Group 1 - Deep Longevity's expansion into the U.S. is a significant milestone, with plans to capture a share of the $6.8 trillion health market [1][2] - The aging clocks developed by Deep Longevity include BloodAge, MindAge, BiometricAge, EpigeneticAge, and the upcoming FaceAge, providing personalized insights for consumers and healthcare providers [1][2] - The company has received support from numerous peer-reviewed papers and patents for its technology, which integrates various biological and psychological factors [2][3] Group 2 - The initial sales focus will be on the Southeastern U.S., including states like Alabama, Florida, and Georgia, with plans to build high-impact partnerships [2] - Deep Longevity's technology offers a vertical software as a service (SaaS) solution that provides personalized recommendations to improve health and extend healthy lifespan [3]

Core Viewpoint - Deep Longevity, Inc. plans to expand into the U.S. market in Q1 2026, targeting the rapidly growing health market valued at over $6.8 trillion [1][2]. Group 1: Expansion Plans - Deep Longevity will establish a local sales team in the U.S., with the first two sales personnel joining on January 1, 2026 [2]. - The initial focus of the sales team will be on the Southeastern U.S. states, including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia [2]. Group 2: Product Offerings - The company offers clinically validated aging clocks, including BloodAge, MindAge, BiometricAge, EpigeneticAge, and the upcoming FaceAge, which provide multi-dimensional biological age assessments beyond chronological age [1][2]. - Deep Longevity's technology is supported by numerous peer-reviewed papers and patents, integrating blood biomarkers, epigenetics, psychology, and biology to deliver comprehensive biological aging profiles [2]. Group 3: Business Model - Deep Longevity provides vertical software-as-a-service (SaaS) solutions that offer personalized recommendations to improve health and extend healthy lifespan [3].